Hospitals are gobbling up M.D. practices at a record rate. In addition to endangering the independent physician practice, this trend is driving up the costs of hospital care by adding ever higher … [Read more...]
MARKET TRENDS
By the Numbers: Spike in M.D. Practice Acquisitions Drives Up Costs of Hospital Care
April 16, 2018
SAFETY
Diagnostic danger in the lab: Time to reform how we process orders
April 16, 2018
By Oleg Bess, M.D. bio I don't know about you, but I was stunned by the findings from a recent report published by Coverys, a national liability insurer, which I feel should put the entire … [Read more...]
NEW PRODUCTS
The Dx Pipeline: A Roundup of the Month’s Key New Product Launches
April 10, 2018
How about an Alexa for verbally querying genetic data? The Amazon Alexa-compatible "digital genetic assistant" from OptraGuru was among the more interesting new offerings of an otherwise … [Read more...]
NEW PRODUCTS
FDA Watch: 23andMe Continues to Spearhead Direct-to-Consumer Marketing of LDT Genetic Tests
April 4, 2018
On March 6, the FDA announced its first ever approval of a direct-to-consumer breast cancer gene test—23andMe's genetic health risk report for detecting BRCA1 and BRCA2 genetic mutations most commonly … [Read more...]
PARTNERSHIPS
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
April 4, 2018
The strategic slowdown in the diagnostics sector continues. Late February to March was relatively light in both deal volume and value, especially compared to the same period in 2017. As usual, the … [Read more...]
MARKETING
Theranos & Its CEO Settle Stock Fraud Charges with SEC
April 4, 2018
Seven years ago, Theranos was a $9 billion dynamo seemingly on the precipice of blowing the blood testing market wide open. Today, the company and its CEO and founder, Elizabeth Holmes, are a … [Read more...]
DISTRIBUTION AGREEMENTS
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
April 3, 2018
Based on the early returns, the market analysts that predicted 2018 would see a slowdown in strategic Dx deal making appear to be right. But while deal volume was low on both the M&A and alliance … [Read more...]
COVERAGE
Emerging Tests: Medicare to Cover Next Gen-Sequencing Tests for Advanced Cancer
March 26, 2018
In the PAMA era, there are two salient trends in Medicare Part B lab reimbursements: Sharply lower prices for traditional tests; and Wider coverage of newly emerging tests, including some that … [Read more...]
INDUSTRY BUZZ
FDA Watch: Personalized Medicine Approvals Continue to Flow
March 19, 2018
After a slow start to the year, new product business picked up significantly in the past four weeks. Here's a rundown of the key diagnostic product launches from mid-January through late … [Read more...]
REIMBURSEMENT
Out of Network: 6 Frequently Asked Questions
March 19, 2018
By Richa Singh bio As labs face an increasingly challenging reimbursement environment, more providers are doubling down on out-of-network strategies to maximize on collections … [Read more...]
